Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127772571 | 12777257 | 1 | I | 2015 | 20160916 | 20160924 | 20160924 | EXP | SI-AMGEN-SVNSP2016128928 | AMGEN | 0.00 | E | M | Y | 0.00000 | 20160924 | MD | SI | SI |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127772571 | 12777257 | 1 | PS | panitumumab | PANITUMUMAB | 1 | Intravenous (not otherwise specified) | UNK UNK, Q3WK (APPLICATIONS EACH THREE WEEKS) | U | 125147 | UNKNOWN FORMULATION | Q3W | |||||||
| 127772571 | 12777257 | 2 | SS | panitumumab | PANITUMUMAB | 1 | U | 125147 | UNKNOWN FORMULATION | ||||||||||
| 127772571 | 12777257 | 3 | SS | NEUPOGEN | FILGRASTIM | 1 | Unknown | UNK | 0 | UNKNOWN FORMULATION | |||||||||
| 127772571 | 12777257 | 4 | C | FOLINIC ACID | LEUCOVORIN | 1 | UNK | 0 | |||||||||||
| 127772571 | 12777257 | 5 | C | FOLINIC ACID | LEUCOVORIN | 1 | 0 | ||||||||||||
| 127772571 | 12777257 | 6 | C | 5-FU | FLUOROURACIL | 1 | UNK | 0 | |||||||||||
| 127772571 | 12777257 | 7 | C | 5-FU | FLUOROURACIL | 1 | 0 | ||||||||||||
| 127772571 | 12777257 | 8 | C | IRINOTECAN | IRINOTECAN | 1 | UNK | 0 | |||||||||||
| 127772571 | 12777257 | 9 | C | IRINOTECAN | IRINOTECAN | 1 | 0 | ||||||||||||
| 127772571 | 12777257 | 10 | C | OXALIPLATIN. | OXALIPLATIN | 1 | UNK | 0 | |||||||||||
| 127772571 | 12777257 | 11 | C | OXALIPLATIN. | OXALIPLATIN | 1 | 0 | ||||||||||||
| 127772571 | 12777257 | 12 | C | XARELTO | RIVAROXABAN | 1 | UNK | 0 | |||||||||||
| 127772571 | 12777257 | 13 | C | FRAGMIN | DALTEPARIN SODIUM | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127772571 | 12777257 | 1 | Rectosigmoid cancer |
| 127772571 | 12777257 | 2 | Rectal stenosis |
| 127772571 | 12777257 | 3 | Product used for unknown indication |
| 127772571 | 12777257 | 4 | Rectosigmoid cancer |
| 127772571 | 12777257 | 5 | Rectal stenosis |
| 127772571 | 12777257 | 6 | Rectosigmoid cancer |
| 127772571 | 12777257 | 7 | Rectal stenosis |
| 127772571 | 12777257 | 8 | Rectosigmoid cancer |
| 127772571 | 12777257 | 9 | Rectal stenosis |
| 127772571 | 12777257 | 10 | Rectosigmoid cancer |
| 127772571 | 12777257 | 11 | Rectal stenosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127772571 | 12777257 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127772571 | 12777257 | Diabetes mellitus | |
| 127772571 | 12777257 | Hypomagnesaemia | |
| 127772571 | 12777257 | Neuropathy peripheral | |
| 127772571 | 12777257 | Skin toxicity |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127772571 | 12777257 | 1 | 2014 | 0 | ||
| 127772571 | 12777257 | 4 | 2014 | 0 | ||
| 127772571 | 12777257 | 6 | 2014 | 0 | ||
| 127772571 | 12777257 | 8 | 2014 | 0 | ||
| 127772571 | 12777257 | 10 | 2015 | 0 |